Breaking LIV Golf Announces Staff Reductions Amidst Shift from Saudi Funding ICE Proposes Legal Insurance for Local Police Assisting Immigration Arrests Dolly Parton’s Life and Career Featured in Visual Retrospective Sal Veder, Photographer Behind Iconic ‘Burst of Joy’ Photo, Dies at 99 Seattle Seahawks Sold to Khosla Family for $9.612 Billion

Wednesday August 26, 2026

Reporter

Akeso, Inc.

7Articles Published

5Communities Covered

Published Articles

Press Release

Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer: HARMONi-GI1 Meets Primary Endpoint

Aug 25

Press Release

/C O R R E C T I O N — Akeso, Inc./

Aug 25

Press Release

Akeso’s AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline

Aug 21

Press Release

Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer

Aug 13

Press Release

Ivonescimab Plus Chemotherapy Approved for First-Line Squamous NSCLC; HARMONi-6 Establishes New Gold Standard in Lung Cancer Treatment

Aug 12

Press Release

Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer

Aug 12

Press Release

Akeso IO2.0 + ADC2.0 Strategy Makes Another Advancement: First Patient Dosed in Phase Ib/II Study of HER3 ADC (AK138D1) Combined with Ivonescimab in Lung Cancer

Jul 27